LOGIN  |  REGISTER
Cue Biopharma
Recursion

Streamline Health Solutions Expands eValuator™ Footprint With Existing Client

April 29, 2024 | Last Trade: US$0.32 0.01 3.28
  • Following an efficient implementation process, a leading Florida-based healthcare provider is expanding its footprint and utilization of eValuator

Atlanta, GA, April 29, 2024 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has expanded its existing contract with a 1,250 bed, Epic-based academic medical center serving central Florida. The health system recently completed its initial implementation of eValuator and has elected to expand its utilization to include additional acquired facilities.

Streamline Health is leading an industry movement to improve hospital financial performance through pre-bill technology solutions. eValuator’s AI-enhanced pre-bill code auditing ensures that providers can accurately capture, bill and ultimately be paid for all the care they provide, while avoiding denials.

“We are thrilled to grow alongside our client so quickly following their eValuator go-live” stated Ben Stilwill, President and Chief Executive Officer, Streamline. “Within a month of go-live our client saw significant ROI, partially driven by our new AI-generated rules. As a result of their experience with Streamline Health’s powerful solution and dedicated team members, the client quickly expanded utilization of eValuator to their new facilities to have a unified platform across the system.”

About Streamline Health

Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net

Contact
Jacob Goldberger
Vice President of Finance
303.887.9625
This email address is being protected from spambots. You need JavaScript enabled to view it.

Astria Therapeutics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB